Genfit: FDA Grants Orphan Drug Status to NTZ Candidate
Genfit has received orphan drug designation from the FDA for NTZ in the treatment of acute hepatic failure on cirrhosis (ACLF). This designation, announced by press release, recognizes the therapeutic profile of the molecule for this indication.
FDA Orphan Drug Designation Achieved
Genfit has secured orphan drug designation from the U.S. Food and Drug Administration for NTZ in the treatment of ACLF (acute hepatic failure on cirrhosis). This designation grants a special status to therapies aimed at treating rare diseases.
Regulatory Benefits of Orphan Drug Status
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning
✓ Euronext data
✓ AI-powered analysis
Indicative data. No investment advice. Unsubscribe at any time.
The orphan drug status provides Genfit with certain regulatory benefits in its development and marketing efforts of the candidate with the U.S. authorities.
Related
🏢
Other stocks — Santé
🗞️
ABL Diagnostics Submits Takeover Bid for Texcell Amid Bankruptcy Proceedings
🗞️
Sensorion Prioritizes SENS-601 as Main Program and Discontinues SENS-501
🗞️
Sanofi Halts Phase 3 MOBILIZE Study on Riliprubart Following Unfavorable Interim Analysis
🗞️
IBA Partners with MD Anderson to Assess Clinical and Economic Value of Proton Therapy
